Calvert Street Announces the Sale of FDS Amplicare

September 9, 2021 - Calvert Street is pleased to announce that it has successfully completed the sale of FDS Amplicare to Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies,  for an all-cash price of $177 million subject to customary adjustments. Calvert Street purchased FDS Amplicare as a platform company to execute a growth strategy focused on providing technology solutions to the retail pharmacy market in the U.S.  FDS Amplicare was successful in building a comprehensive suite of SaaS-based technology offerings to help pharmacies communicate with their patients, gain actionable insights into their operations and improve population health.   Over the course of our ownership, FDS Amplicare has increased its revenues fivefold through a combination of organic and acquisition related growth. Omnicell purchased FDS Amplicare to augment its EnlivenHealth™ Division.

Adam McMullin, CEO of FDS Amplicare prior to the sale to Omnicell, commented: “FDS Amplicare is a great story and I am excited about the combination with Omnicell. Pharmacies play a critical role in the growing demand for community-based healthcare. As we looked at the best way to continue serving the market, joining together with Omnicell’s EnlivenHealth division was the best path for the company and its shareholders.”

Michael Booth, Partner at Calvert Street, added, “FDS Amplicare is a great example of how we build value using a thesis-based investing approach.  We are very pleased with this result and we were proud to partner with Adam McMullin and the entire FDS Amplicare team to build such a valuable and innovative company.”    

 

ABOUT FDS Amplicare

FDS Amplicare strengthens the health of pharmacies and their patients.  We are leading the transition to community-based population health by providing technology solutions focused on financial management, data analytics, patient communication and clinical services. Our suite of  services enables pharmacies to thrive now and into the future.  For more information, please visit www.fdsrx.com and www.amplicare.com.

 

ABOUT CALVERT STREET

Calvert Street is a Baltimore, Maryland-based private equity firm focused on investing in businesses in the lower middle market in targeted, thesis-led industry sectors. Calvert Street partners with founders, families and skilled management teams of privately held businesses to drive profitable growth and organizational transformation. Since its inception in 1995, Calvert Street’s managed funds have invested over $685 million in over 90 companies (45 platform acquisitions and 46 add-ons).

For more information, please visit www.cscp.com

 

ABOUT OMNICELL

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings.  Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. More than 60,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell’s innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

To learn more, visit www.omnicell.com.

OMNICELL and AMPLICARE are registered trademarks and ENLIVENHEALTH is a trademark of Omnicell, Inc. or one of its subsidiaries.